News

The approval was supported by the pivotal phase 3 THRIVE and THRIVE-2 trials, which evaluated veligrotug in active and chronic TED.

Healthcare leaders rank improving the patient experience ahead of digital transformation and cost reduction, and it can't be done without a trusted identity foundation.

Rather than considering prior authorization metrics separately, a Friction Index combines,

The approach of pairing an ecological framework with AI methods offers a new way to identify where diabetes risk concentrates.

Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of the disease.

Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation.

A new meta-analysis suggests that combining immunotherapy and chemotherapy might be the best choice for treating advanced non-small cell lung cancer.

Addressing social determinants of health is now a strategic pillar of organizational planning, compliance, and long-term sustainability.

Results from the DAPHNe trial point to ctDNA as having a role in guiding treatment, but the researchers and a commentator say more research needs to be done before determining exactly what it is.

The two conditions can have similar manifestations but differ in prognosis and treatment, which makes an accurate, early diagnosis important.

Survodutide is a dual GLP-1/glucagon receptor agonist that was also able to normalize liver fat in 61% of patients with metabolic dysfunction-associated steatotic liver disease.

Kutscher says MDVIP is expanding into specialty care and eyeing pediatrics.

If prospective studies of clinical outcomes confirm the findings, one near-term application of the research might be using automated analysis of speech samples to monitor patients with schizophrenia.

Lung cancer has shifted from a rare, smoking-driven disease to one increasingly seen in young non-smokers, especially women, with possible links to pesticide exposure from otherwise “healthy” diets.

In this discussion, Jorge Nieva, M.D., professor of clinical medicine at the University of Southern California Norris Comprehensive Cancer Center, explores how pesticide exposure from otherwise “healthy” diets may help explain the rise of early-onset lung cancer in non-smokers.

The healthcare industry succeeded in making behavioral healthcare more accessible, argues Machinify's Lisa Pincher. Now, it must build the infrastructure to support that care responsibly.

Hofstra University and Northwell Health’s jointly founded medical school has secured funding from the National Institutes of Health for its combined M.D./Ph.D. program.

The Lown Institute’s annual social responsibility index gave the Ohio and Philadelphia systems the highest marks.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, says that when used together, the numeric pain score and function scores give clinicians a far more complete clinical picture of a patient’s pain.

If approved, cemdisiran could be the first RNAi therapeutic to treat generalized myasthenia gravis that would be dosed every 12 weeks.

The findings add to the evidence that targeted therapies can improve outcomes in early-stage, oncogene-driven lung cancers, say the study's authors.

An electronic health record–based diabetes risk tool helped primary care teams target prevention and reduce progression to type 2 diabetes in prediabetes patients.

David Blair, CEO of LucyRx, and Jason Borschow, CEO of Abarca, spoke to Managed Healthcare Executive about the company’s merger and how the combined company is positioned for the PBM market of the future.

Skinvive by Juvéderm recently received FDA approval as the first hyaluronic acid injectable indicated for reducing horizontal neck lines, with 74.8% of trial participants achieving clinically significant improvement at one month.

Healthcare leaders need to treat artificial intelligence (AI) adoption as an operating model question, not just a matter of IT staffing.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, argues that function-based tools offer a more equitable and clinically meaningful approach to pain management.

The FDA has expanded Capvaxive approval to include 2- to 17-year-olds at increased risk of pneumococcal disease, making it the only pneumococcal conjugate vaccine approved for this population in the United States.

A CDC-led test-negative case-control study using the VISION network found that the 2024-2025 COVID-19 vaccine reduced the odds of medically attended COVID-19 in adults, with an effectiveness of 26% against emergency department/urgent care encounters, 35% against hospitalization and 41% against critical illness, benefits that held up in older adults and immunocompromised patients but waned over time since vaccination.